Clinical Trials Browser

Phase 1/2 × Breast Neoplasms × Paclitaxel × Clear all

NCT02734290 2026-04-24

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03742102 2026-04-24

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01980277 2026-04-21

TAKTIC

Phase 1/2 Terminated

Breast Neoplasms

NCT03568422 2026-03-27

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Phase 1/2 Active not recruiting

37 enrolled 14 charts

Breast Neoplasms

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT04644068 2026-02-19

PETRA

Phase 1/2 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Phase 1/2 Active not recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT01084863 2025-01-24

Compare

Phase 1/2 Completed

143 enrolled 23 charts

Breast Neoplasms

NCT03601897 2024-12-27

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

177 enrolled 25 charts

BreastGynecologicSarcoma

Breast Neoplasms, Carcinosarcoma, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02938442 2024-11-07

Vaccination of Triple Negative Breast Cancer Patients

Phase 1/2 Completed

16 enrolled 30 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Phase 1/2 Completed

51 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01306942 2023-03-30

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Phase 1/2 Completed

37 enrolled 30 charts

Breast Neoplasms

NCT01134250 2022-04-15

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Phase 1/2 Completed

BreastDermatologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

NCT02041429 2021-04-21

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Phase 1/2 Completed

20 enrolled 23 charts

Breast Neoplasms

NCT00470301 2021-02-16

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Completed

60 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01495247 2020-12-08

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00574587 2020-10-14

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Phase 1/2 Completed

55 enrolled 10 charts

Breast Neoplasms

NCT01697293 2020-09-24

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT00003086 2020-07-14

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT02628132 2020-07-07

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Phase 1/2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01484080 2020-01-27

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Phase 1/2 Completed

Breast Neoplasms

NCT00820170 2019-08-13

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Phase 1/2 Completed

55 enrolled 19 charts

Breast Neoplasms, Neoplasms

NCT02297230 2018-10-15

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

Phase 1/2 Terminated

44 enrolled 6 charts

Breast Neoplasms

NCT01031446 2018-08-31

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

55 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00445458 2018-07-26

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Phase 1/2 Completed

110 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT01512199 2017-10-18

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00041470 2017-07-17

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Phase 1/2 Terminated

38 enrolled 6 charts

Breast Neoplasms

NCT02396108 2017-02-03

Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT01172223 2016-11-02

LAPADO

Phase 1/2 Completed

Breast Neoplasms

NCT00691379 2016-09-22

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Phase 1/2 Completed

Breast Neoplasms

NCT00887575 2016-09-07

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 1/2 Completed

54 enrolled 11 charts

Breast Neoplasms

NCT00951665 2016-06-24

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

107 enrolled 31 charts

Breast Neoplasms

NCT01042925 2016-06-03

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Phase 1/2 Completed

Breast Neoplasms

NCT00900627 2016-01-20

THYME

Phase 1/2 Completed

330 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00368875 2015-11-05

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Phase 1/2 Completed

54 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01764087 2015-05-18

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Phase 1/2 Unknown

BreastGastrointestinal

Breast Neoplasms, Carcinoma, Neoplasms, Stomach Neoplasms

NCT00022230 2015-05-05

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT00054028 2015-03-17

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

Phase 1/2 Completed

31 enrolled 16 charts

Breast Neoplasms

NCT02015676 2015-03-12

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Completed

69 enrolled 18 charts

Breast Neoplasms

NCT00002627 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00002628 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms